William Blair Has Positive Estimate for Penumbra Q1 Earnings

Penumbra, Inc. (NYSE:PEN) – Equities research analysts at William Blair raised their Q1 2025 EPS estimates for Penumbra in a research note issued on Thursday, October 31st. William Blair analyst M. Kaczor now anticipates that the company will post earnings of $0.79 per share for the quarter, up from their previous forecast of $0.72. The consensus estimate for Penumbra’s current full-year earnings is $2.72 per share. William Blair also issued estimates for Penumbra’s Q2 2025 earnings at $1.00 EPS.

Other equities research analysts have also issued reports about the stock. Leerink Partners initiated coverage on shares of Penumbra in a report on Tuesday, September 3rd. They set an “outperform” rating and a $263.00 price objective for the company. Canaccord Genuity Group boosted their price target on shares of Penumbra from $176.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Morgan Stanley cut their price objective on Penumbra from $235.00 to $210.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Robert W. Baird boosted their target price on Penumbra from $244.00 to $248.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Citigroup raised their price target on Penumbra from $178.00 to $200.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Five analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $226.67.

Penumbra Stock Performance

NYSE:PEN opened at $232.39 on Monday. The stock has a 50-day moving average price of $201.95 and a 200 day moving average price of $194.14. The stock has a market capitalization of $8.92 billion, a P/E ratio of 270.22, a P/E/G ratio of 2.54 and a beta of 0.51. Penumbra has a 12-month low of $148.00 and a 12-month high of $277.34. The company has a current ratio of 5.82, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last issued its earnings results on Wednesday, October 30th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.16. The company had revenue of $301.04 million during the quarter, compared to the consensus estimate of $297.36 million. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. Penumbra’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 EPS.

Institutional Trading of Penumbra

A number of hedge funds and other institutional investors have recently bought and sold shares of PEN. Los Angeles Capital Management LLC boosted its stake in shares of Penumbra by 512.6% during the third quarter. Los Angeles Capital Management LLC now owns 9,826 shares of the company’s stock valued at $1,909,000 after purchasing an additional 8,222 shares during the period. State of New Jersey Common Pension Fund D boosted its position in Penumbra by 3.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 13,558 shares of the company’s stock valued at $2,634,000 after buying an additional 469 shares during the period. Crossmark Global Holdings Inc. grew its stake in Penumbra by 16.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 2,960 shares of the company’s stock worth $575,000 after acquiring an additional 422 shares in the last quarter. Washington Trust Advisors Inc. increased its position in shares of Penumbra by 2.6% during the third quarter. Washington Trust Advisors Inc. now owns 21,506 shares of the company’s stock worth $4,179,000 after acquiring an additional 541 shares during the period. Finally, SpiderRock Advisors LLC bought a new stake in shares of Penumbra during the third quarter valued at approximately $514,000. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Insider Activity at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $175.98, for a total transaction of $105,588.00. Following the completion of the transaction, the executive vice president now directly owns 61,688 shares of the company’s stock, valued at $10,855,854.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Adam Elsesser sold 1,620 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $200.00, for a total value of $324,000.00. Following the sale, the chief executive officer now directly owns 925,962 shares in the company, valued at approximately $185,192,400. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $175.98, for a total value of $105,588.00. Following the transaction, the executive vice president now owns 61,688 shares of the company’s stock, valued at approximately $10,855,854.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,368 shares of company stock worth $6,893,118. Company insiders own 5.00% of the company’s stock.

Penumbra announced that its Board of Directors has initiated a share repurchase plan on Tuesday, August 13th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy up to 2.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.